Neuigkeiten WKN: A14UCN ISIN: US30050B1017 Kürzel: EVH Forum: Aktien User: sz78

Evolent Health is experiencing strong momentum with over $750 million in new annualized revenue slated for 2026, driven by high demand for its complex specialty care, particularly in oncology and cardiology. The pipeline is supported by strong, long-term customer retention and a "remaining pipeline" exceeding $650 million. PR Newswire PR Newswire +2 Key Pipeline and Growth Drivers (2026 Outlook): Revenue & Growth: Full-year 2026 revenue is expected to range between $2.4 billion and $2.6 billion. New Partnerships: In late 2025, Evolent announced 13 new revenue agreements for 2026, including a large regional Blues plan adopting its Oncology Performance Suite for over 650,000 members. Core Offerings: The pipeline is heavily focused on AI-driven analytics, clinical decision support, and value-based care, particularly for complex, high-cost patient populations (cancer, cardiology, musculoskeletal). Strategic Focus: The company is focusing on expanding its "Performance Suite" and "Technology & Services Suite" across existing and new payer/provider clients. Evolent Evolent +3 Evolent’s strategy involves transitioning from being just a tech vendor to providing end-to-end clinical and operational support, which has bolstered their sales pipeline. Investing.com Investing.com +1